Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
REVB
Upturn stock ratingUpturn stock rating

Revelation Biosciences Inc (REVB)

Upturn stock ratingUpturn stock rating
$2.58
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: REVB (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $60

1 Year Target Price $60

Analysts Price Target For last 52 week
$60 Target price
52w Low $2.11
Current$2.58
52w High $100.32

Analysis of Past Performance

Type Stock
Historic Profit -22.22%
Avg. Invested days 8
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.39M USD
Price to earnings Ratio -
1Y Target Price 60
Price to earnings Ratio -
1Y Target Price 60
Volume (30-day avg) 1
Beta -0.05
52 Weeks Range 2.11 - 100.32
Updated Date 08/15/2025
52 Weeks Range 2.11 - 100.32
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) 866.22

Earnings Date

Report Date 2025-08-08
When -
Estimate -9
Actual -7.01

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -57.37%
Return on Equity (TTM) -340.81%

Valuation

Trailing PE -
Forward PE 0.89
Enterprise Value -788808
Price to Sales(TTM) 2.88
Enterprise Value -788808
Price to Sales(TTM) 2.88
Enterprise Value to Revenue -
Enterprise Value to EBITDA -1.02
Shares Outstanding 1699640
Shares Floating 1684289
Shares Outstanding 1699640
Shares Floating 1684289
Percent Insiders 0.9
Percent Institutions 0.81

ai summary icon Upturn AI SWOT

Revelation Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Revelation Biosciences Inc. is a clinical-stage biopharmaceutical company focused on the development of immunomodulatory therapies for the prevention and treatment of disease. Founded in 2011, they have evolved from initially focusing on respiratory diseases to a broader range of inflammatory and infectious diseases. They are using their REVTx-99 platform.

business area logo Core Business Areas

  • REVTx-99: Intranasal immunomodulator being developed for prevention of respiratory viral infections.
  • REVTx-300: Being developed as a potential therapy for chronic organ inflammation, and has the potential to improve clinical outcomes in inflammatory bowel disease.
  • REVBx-100: A diagnostic aid for detection of potential tissue damage secondary to ischemic events. A biomarker panel for early diagnosis of acute kidney injury (AKI) during surgical procedures.

leadership logo Leadership and Structure

James Rolke is the CEO. The company operates with a typical biotech organizational structure, with departments focused on research and development, clinical trials, regulatory affairs, and business development.

Top Products and Market Share

overview logo Key Offerings

  • REVTx-99: An intranasal spray being developed for preventing respiratory viral infections, including influenza and SARS-CoV-2. Currently in clinical trials. Market share is currently 0 as it is not yet approved. Competitors include companies developing vaccines and antiviral therapies for respiratory viruses, such as Pfizer (Paxlovid), Moderna (mRNA vaccines) and Gilead (Tamiflu).
  • REVTx-300: An investigational product for the treatment of inflammatory bowel disease. Market share is currently 0 as it is not yet approved. Competitors include companies that make anti-inflammatory drugs such as Takeda(Entyvio), Abbvie(Humira), and Janssen Biotech (Stelara).
  • REVBx-100: A diagnostic aid for early detection of Acute Kidney Injury in hospitals. Market share is currently 0 as it is not yet approved. Key competitors are bioMu00e9rieux (Astute Medical) and Beckman Coulter(Dx).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Recent trends include increased focus on personalized medicine, gene therapy, and immunomodulatory therapies.

Positioning

Revelation Biosciences is a clinical-stage company aiming to establish itself in the immunomodulatory therapeutics market. Competitive advantages will depend on clinical trial success and regulatory approvals.

Total Addressable Market (TAM)

The TAM for respiratory viral infection preventatives and inflammatory bowel disease treatments are each multi-billion dollar markets. REV is currently in a developing stage and is positioned to capture a portion of these markets if trials are successful.

Upturn SWOT Analysis

Strengths

  • Novel immunomodulatory technology platform
  • Experienced management team
  • Diverse pipeline of product candidates

Weaknesses

  • Clinical stage company with no approved products and no revenue
  • Dependence on successful clinical trial outcomes
  • High cash burn rate

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline through acquisitions or licensing
  • Advancements in regulatory pathways for immunomodulatory therapies

Threats

  • Failure to obtain regulatory approvals
  • Competition from established pharmaceutical companies
  • Unfavorable clinical trial results
  • Limited funding

Competitors and Market Share

competitor logo Key Competitors

  • MRNA
  • PFE
  • ABBV
  • TAK
  • JNJ
  • GILD

Competitive Landscape

Revelation Biosciences faces strong competition from established pharmaceutical companies with greater resources and approved products. Its success hinges on demonstrating superior efficacy and safety of its product candidates.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by increased R&D spending and clinical trial activity.

Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals for REVTx-99 and REVTx-300. Analyst estimates are speculative and highly dependent on these factors.

Recent Initiatives: Recent initiatives include advancing REVTx-99 into Phase 2 clinical trials and exploring partnerships for further development of the pipeline.

Summary

Revelation Biosciences is a high-risk, high-reward clinical-stage biopharmaceutical company. Its novel immunomodulatory technology holds promise, but success is contingent on positive clinical trial results and regulatory approvals. Financial stability is a key concern, requiring continuous funding.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and is subject to change. Investment decisions should be made after consulting with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Revelation Biosciences Inc

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2020-11-17
Chairman & CEO Mr. James M. Rolke
Sector Healthcare
Industry Biotechnology
Full time employees 8
Full time employees 8

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.